Intra-arterial treatment with 90yttrium microspheres in treatment-refractory and unresectable liver metastases of neuroendocrine tumors and the use of 111in-octreotide scintigraphy in the evaluation of treatment response.
Identifieur interne : 001318 ( Main/Exploration ); précédent : 001317; suivant : 001319Intra-arterial treatment with 90yttrium microspheres in treatment-refractory and unresectable liver metastases of neuroendocrine tumors and the use of 111in-octreotide scintigraphy in the evaluation of treatment response.
Auteurs : RBID : pubmed:21950557English descriptors
- KwdEn :
- Adult, Aged, Female, Humans, Infusions, Intra-Arterial, Liver Neoplasms (drug therapy), Liver Neoplasms (radionuclide imaging), Liver Neoplasms (secondary), Male, Microspheres, Middle Aged, Neoplasm Metastasis, Neuroendocrine Tumors (drug therapy), Neuroendocrine Tumors (pathology), Neuroendocrine Tumors (radionuclide imaging), Octreotide (analogs & derivatives), Octreotide (diagnostic use), Radionuclide Imaging, Radiotherapy Dosage, Survival Analysis, Treatment Outcome, Yttrium Radioisotopes (therapeutic use).
- MESH :
- chemical , analogs & derivatives : Octreotide.
- chemical , diagnostic use : Octreotide.
- drug therapy : Liver Neoplasms, Neuroendocrine Tumors.
- pathology : Neuroendocrine Tumors.
- radionuclide imaging : Liver Neoplasms, Neuroendocrine Tumors.
- secondary : Liver Neoplasms.
- chemical , therapeutic use : Yttrium Radioisotopes.
- Adult, Aged, Female, Humans, Infusions, Intra-Arterial, Male, Microspheres, Middle Aged, Neoplasm Metastasis, Radionuclide Imaging, Radiotherapy Dosage, Survival Analysis, Treatment Outcome.
Abstract
The aim of this study was to examine the efficacy of intra-arterial (90)Yttrium treatment in the management of unresectable hepatic neuroendocrine tumors (NET) metastases unresponsive to treatment and the role of (111)In-octreotide scintigraphy in the evaluation of treatment response.
DOI: 10.1089/cbr.2011.0957
PubMed: 21950557
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Intra-arterial treatment with 90yttrium microspheres in treatment-refractory and unresectable liver metastases of neuroendocrine tumors and the use of 111in-octreotide scintigraphy in the evaluation of treatment response.</title><author><name sortKey="Lacin, Seda" uniqKey="Lacin S">Seda Lacin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Nuclear Medicine, Ankara University Medical Faculty, Ankara, Turkey.</nlm:affiliation><country xml:lang="fr">Turquie</country><wicri:regionArea>Department of Nuclear Medicine, Ankara University Medical Faculty, Ankara</wicri:regionArea></affiliation></author><author><name sortKey="Oz, Ilker" uniqKey="Oz I">Ilker Oz</name></author><author><name sortKey="Ozkan, Elgin" uniqKey="Ozkan E">Elgin Ozkan</name></author><author><name sortKey="Kucuk, Ozlem" uniqKey="Kucuk O">Ozlem Kucuk</name></author><author><name sortKey="Bilgic, Sadik" uniqKey="Bilgic S">Sadik Bilgic</name></author></titleStmt><publicationStmt><date when="2011">2011</date><idno type="doi">10.1089/cbr.2011.0957</idno><idno type="RBID">pubmed:21950557</idno><idno type="pmid">21950557</idno><idno type="wicri:Area/Main/Corpus">001134</idno><idno type="wicri:Area/Main/Curation">001134</idno><idno type="wicri:Area/Main/Exploration">001318</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Infusions, Intra-Arterial</term><term>Liver Neoplasms (drug therapy)</term><term>Liver Neoplasms (radionuclide imaging)</term><term>Liver Neoplasms (secondary)</term><term>Male</term><term>Microspheres</term><term>Middle Aged</term><term>Neoplasm Metastasis</term><term>Neuroendocrine Tumors (drug therapy)</term><term>Neuroendocrine Tumors (pathology)</term><term>Neuroendocrine Tumors (radionuclide imaging)</term><term>Octreotide (analogs & derivatives)</term><term>Octreotide (diagnostic use)</term><term>Radionuclide Imaging</term><term>Radiotherapy Dosage</term><term>Survival Analysis</term><term>Treatment Outcome</term><term>Yttrium Radioisotopes (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Octreotide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Octreotide</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Liver Neoplasms</term><term>Neuroendocrine Tumors</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Neuroendocrine Tumors</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Liver Neoplasms</term><term>Neuroendocrine Tumors</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Liver Neoplasms</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Yttrium Radioisotopes</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Female</term><term>Humans</term><term>Infusions, Intra-Arterial</term><term>Male</term><term>Microspheres</term><term>Middle Aged</term><term>Neoplasm Metastasis</term><term>Radionuclide Imaging</term><term>Radiotherapy Dosage</term><term>Survival Analysis</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aim of this study was to examine the efficacy of intra-arterial (90)Yttrium treatment in the management of unresectable hepatic neuroendocrine tumors (NET) metastases unresponsive to treatment and the role of (111)In-octreotide scintigraphy in the evaluation of treatment response.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">21950557</PMID><DateCreated><Year>2011</Year><Month>10</Month><Day>13</Day></DateCreated><DateCompleted><Year>2012</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-8852</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>5</Issue><PubDate><Year>2011</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Cancer biotherapy & radiopharmaceuticals</Title><ISOAbbreviation>Cancer Biother. Radiopharm.</ISOAbbreviation></Journal><ArticleTitle>Intra-arterial treatment with 90yttrium microspheres in treatment-refractory and unresectable liver metastases of neuroendocrine tumors and the use of 111in-octreotide scintigraphy in the evaluation of treatment response.</ArticleTitle><Pagination><MedlinePgn>631-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1089/cbr.2011.0957</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The aim of this study was to examine the efficacy of intra-arterial (90)Yttrium treatment in the management of unresectable hepatic neuroendocrine tumors (NET) metastases unresponsive to treatment and the role of (111)In-octreotide scintigraphy in the evaluation of treatment response.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Thirteen (13) patients with a mean age of 53.3 years not eligible for surgical treatment were included. Before the procedure, routine tests for renal/hepatic functions and bilirubin levels as well as (99m)Tc-macroaggregated albumin test to detect any leakage to the lungs were done. Treatment doses were calculated using body surface area method and all patients received (90)Y resin microspheres through hepatic artery catheter. Abdominopelvic computed tomography (CT) and (111)In-octreotide scintigraphy were done before and after treatment. Patients were divided into two groups based on their treatment response as assessed by either (111)In-octreotide scintigraphy or CT: group 1, responders; group 2, nonresponders.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">For all patients, 1-year survival rate and overall survival was 84.7% and 20 months, respectively. Based on (111)In-octreotide scintigraphy findings, 1-year survival rate was 90% and 66.7% for responders and nonresponders, respectively, whereas corresponding overall survival was 21.3 months and 15.3 months. Survival data based on CT findings were as follows: 1-year survival rate, responders, 80%; nonresponders, 100%; overall survival, responders, 20.4 months, nonresponders, 18.5 months.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Intra-arterial treatment with (90)Y has survival benefits in treatment-refractory liver metastases from NETs and it could be used in these patients. Since it is a functional imaging method, (111)In-octreotide scintigraphy may be better discriminates patients responding to treatment from patients not responding.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lacin</LastName><ForeName>Seda</ForeName><Initials>S</Initials><Affiliation>Department of Nuclear Medicine, Ankara University Medical Faculty, Ankara, Turkey.</Affiliation></Author><Author ValidYN="Y"><LastName>Oz</LastName><ForeName>Ilker</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Ozkan</LastName><ForeName>Elgin</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Kucuk</LastName><ForeName>Ozlem</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Bilgic</LastName><ForeName>Sadik</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Clinical Trial</PublicationType><PublicationType>Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cancer Biother Radiopharm</MedlineTA><NlmUniqueID>9605408</NlmUniqueID><ISSNLinking>1084-9785</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Yttrium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>indium-111-octreotide</NameOfSubstance></Chemical><Chemical><RegistryNumber>RWM8CCW8GP</RegistryNumber><NameOfSubstance>Octreotide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Infusions, Intra-Arterial</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Liver Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y">drug therapy</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName><QualifierName MajorTopicYN="N">secondary</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Microspheres</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasm Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neuroendocrine Tumors</DescriptorName><QualifierName MajorTopicYN="Y">drug therapy</QualifierName><QualifierName MajorTopicYN="N">pathology</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Octreotide</DescriptorName><QualifierName MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radionuclide Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiotherapy Dosage</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Yttrium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="aheadofprint"><Year>2011</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1089/cbr.2011.0957</ArticleId><ArticleId IdType="pubmed">21950557</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001318 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001318 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:21950557
|texte= Intra-arterial treatment with 90yttrium microspheres in treatment-refractory and unresectable liver metastases of neuroendocrine tumors and the use of 111in-octreotide scintigraphy in the evaluation of treatment response.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21950557" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |